GLP-1 is a hormone involved in appetite and glucose regulation. Medications that activate its receptor can reduce food intake through effects on appetite, while also changing how the body manages blood glucose.[1]
Appetite and glucose are connected effects
Semaglutide activates the GLP-1 receptor. The approved medication increases insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Insulin helps manage glucose, while glucagon signals the body to increase glucose availability.[1]
Its weight-management effect also involves reduced calorie intake. Feeling less hungry is part of the intended action, although the experience varies between people.
Digestion changes too
Semaglutide delays gastric emptying, which means food leaves the stomach more slowly. Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are among its common adverse reactions.[1]
Digestive symptoms are not a measure of how well treatment is working. Persistent symptoms that interfere with eating or drinking belong in the treatment review.
Why tirzepatide is described differently
Tirzepatide acts at both GIP and GLP-1 receptors. GIP is another hormone signal involved in glucose regulation. This dual action distinguishes its mechanism from a medication acting only at GLP-1 receptors.[2]
Suitability and response depend on the specific medication, health history, tolerability, and treatment course.
The product still matters
Prescribing information and trials describe particular FDA-approved products. Compounded semaglutide and tirzepatide are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before marketing.[3]
A discussion about treatment should identify the exact preparation and the medical reason for considering it.
